Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoshi Gandan granules is a traditional Chinese medicine (TCM) formulation currently in Phase III clinical development for the treatment of chronic cholecystitis, specifically for patients presenting with the liver-gallbladder damp-heat syndrome. Developed by Guangzhou Boji New Drug Clinical Research Center, the drug is administered orally as a granule. The therapeutic objective is to alleviate clinical symptoms, primarily right upper quadrant abdominal pain, by addressing the underlying TCM pattern of damp-heat in the liver and gallbladder. As a multi-herb TCM product, its mechanism involves a holistic approach to clearing heat and promoting gallbladder function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoshi Gandan granules.